$CAMP News

CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder

CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates

CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights

Camp4 Therapeutics Q1 EPS $(0.32) Misses $(0.29) Estimate, Sales $1.294M Beat $300.000K Estimate

CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation

CAMP4 Therapeutics Submits Reprint To bioRxiv Titled "Profiling and Targeting of Regulatory RNAs to Upregulate Gene Expression."

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rodman & Renshaw Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $7

CAMP4 Therapeutics Unveils Gene-Upregulation ASO Platform, Targets SYNGAP1 Clinic Entry in 2H

Leerink Partners Maintains Outperform on Camp4 Therapeutics, Raises Price Target to $9

CAMP4 Appoints Michael MacLean to its Board of Directors

Biotech Alert: Searches spiking for these stocks today

CAMP4 Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 67.62%

CAMP4 Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 67.62%

Camp4 Therapeutics: Strong Cash Runway As CMP-002 Moves Toward Human Trials

CAMP4 to Participate in Upcoming Investor Conferences

CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights

Camp4 Therapeutics Earnings Review: Q4 Summary

Camp4 Therapeutics Q4 EPS $(0.87) Misses $(0.30) Estimate, Sales $348.000K Miss $538.000K Estimate

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)